Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short term Debt (2020 - 2022)

Arcturus Therapeutics Holdings (ARCT) has disclosed Short term Debt for 3 consecutive years, with $60.7 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Short term Debt rose 169.89% year-over-year to $60.7 million, compared with a TTM value of $60.7 million through Dec 2022, up 169.89%, and an annual FY2022 reading of $60.7 million, up 169.89% over the prior year.
  • Short term Debt was $60.7 million for Q4 2022 at Arcturus Therapeutics Holdings, up from $27.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $60.7 million in Q4 2022 and bottomed at $1.2 million in Q4 2020.
  • Average Short term Debt over 3 years is $26.0 million, with a median of $24.3 million recorded in 2022.
  • The sharpest move saw Short term Debt surged 1697.92% in 2021, then soared 49.89% in 2022.
  • Year by year, Short term Debt stood at $1.2 million in 2020, then soared by 1697.92% to $22.5 million in 2021, then soared by 169.89% to $60.7 million in 2022.
  • Business Quant data shows Short term Debt for ARCT at $60.7 million in Q4 2022, $27.7 million in Q3 2022, and $27.0 million in Q2 2022.